Original article
The Prevention of Medication-related Osteonecrosis of the Jaw
Dtsch Arztebl Int 2017; 114: 63-9. DOI: 10.3238/arztebl.2017.0063
; ; ;
| 1. | Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D: Epidemiology, treatment and costs of osteoporosis in Germany— the BoneEVA Study. Osteoporos Int 2007; 18: 77–84 CrossRef MEDLINE |
| 2. | Liu J, Huang W, Zhou R, et al.: Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: a meta-analysis. Medicine 2015; 94: e2014 MEDLINE MEDLINE PubMed Central |
| 3. | Pazianas M, Abrahamsen B: Safety of bisphosphonates. Bone 2011; 49: 103–10 CrossRef MEDLINE |
| 4. | Walter C, Al-Nawas B, Frickhofen N, et al.: Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010; 6: 11 CrossRef MEDLINE PubMed Central |
| 5. | Kyle RA, Yee GC, Somerfield MR, et al.: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464–72 CrossRef MEDLINE |
| 6. | Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005; 353: 99–10 CrossRef MEDLINE |
| 7. | Edwards BJ, Bunta AD, Lane J, et al.: Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am 2013; 95: 297–307 CrossRef MEDLINE PubMed Central |
| 8. | Ruggiero SL, Dodson TB, Fantasia J, et al.: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014; 72: 1938–56 CrossRef CrossRef MEDLINE |
| 9. | Licata AA: Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005; 39: 668–77 CrossRef MEDLINE |
| 10. | Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ: The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001; 44: 2201–10 CrossRef |
| 11. | Bamias A, Kastritis E, Bamia C, et al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580–7 CrossRef MEDLINE |
| 12. | Lo JC, O’Ryan FS, Gordon NP, et al.: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243–53 CrossRef MEDLINE |
| 13. | Tsao C, Darby I, Ebeling PR, et al.: Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013; 71: 1360–6 CrossRef MEDLINE |
| 14. | Vahtsevanos K, Kyrgidis A, Verrou E, et al.: Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27: 5356–62 CrossRef MEDLINE |
| 15. | Saad F, Brown JE, Van Poznak C, et al.: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341–7 CrossRef MEDLINE |
| 16. | Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–7 CrossRef |
| 17. | Bonacina R, Mariani U, Villa F, Villa A: Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011; 77: b147 MEDLINE |
| 18. | Dimopoulos MA, Kastritis E, Bamia C, et al.: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117–20 CrossRef MEDLINE |
| 19. | Ferlito S, Liardo C, Puzzo S: Dental extractions in patient treated with intravenous bisphosphonates and risk of osteonecrosis of jaws: presentation of a preventive protocol and case series. Minerva Stomatol 2010; 59: 593–601 MEDLINE |
| 20. | Heufelder MJ, Hendricks J, Remmerbach T, Frerich B, Hemprich A, Wilde F: Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: e429–35 CrossRef MEDLINE |
| 21. | Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A: Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg 2010; 68: 107–10 CrossRef MEDLINE |
| 22. | Mozzati M, Arata V, Gallesio G, Carossa S: A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint Bone Spine 2011; 78: 648–9 CrossRef MEDLINE |
| 23. | Regev E, Lustmann J, Nashef R: Atraumatic teeth extraction in bisphosphonate-treated patients. J Oral Maxillofac Surg 2008; 66: 1157–61 CrossRef MEDLINE |
| 24. | Scoletta M, Arata V, Arduino PG, et al.: Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg 2013; 71: 994–9 CrossRef MEDLINE |
| 25. | Vandone AM, Donadio M, Mozzati M, et al.: Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 2012; 23: 193–200 CrossRef MEDLINE |
| 26. | Vescovi P, Meleti M, Merigo E, et al.: Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal 2013; 18: e680–5 CrossRef MEDLINE PubMed Central |
| 27. | Ripamonti CI, Maniezzo M, Campa T, et al.: Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137–45 CrossRef MEDLINE |
| 28. | Sim Ie W, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR: Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. J Clin Endocrinol Metab 2015; 100: 3887–93 CrossRef MEDLINE |
| 29. | Bramati A, Girelli S, Farina G, et al.: Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 2015; 33: 119–24 CrossRef MEDLINE |
| 30. | Scoletta M, Arduino PG, Pol R, et al.: Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. J Oral Maxillofac Surg 2011; 69: 456–62 CrossRef MEDLINE |
| 31. | Kyrgidis A, Vahtsevanos K, Koloutsos G, et al.: Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26: 4634–8 CrossRef MEDLINE |
| 32. | Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S: Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007; 18: 1363–70 CrossRef MEDLINE |
| 33. | Molcho S, Peer A, Berg T, Futerman B, Khamaisi M: Diabetes microvascular disease and the risk for bisphosphonate-related osteonecrosis of the jaw: a single center study. J Clin Endocrinol Metab 2013; 98: E1807–12 CrossRef MEDLINE |
| 34. | Montefusco V, Gay F, Spina F, et al.: Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49: 2156–62 CrossRef MEDLINE |
| 35. | Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB: Incidence and mortality of hip fractures in the United States. JAMA 2009; 302: 1573–9 CrossRef MEDLINE PubMed Central |
| 36. | McClung M, Harris ST, Miller PD, et al.: Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126: 13–20 CrossRef MEDLINE |
| 37. | Saad F, Lipton A: Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007; 34: S17–23 CrossRef MEDLINE |
| 38. | Grötz K, Piesold JU, Al-Nawas B: Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF Online 2012; AWMF Register-Nr. 007/091. |
| 39. | Hoff AO, Toth BB, Altundag K, et al.: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826–36 CrossRef MEDLINE PubMed Central |
| 40. | Voss PJ, Joshi Oshero J, Kovalova-Muller A, et al.: Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg 2012; 40: 719–25 CrossRef MEDLINE |
| e1. | Dunford JE, Thompson K, Coxon FP, et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235–42. |
| e2. | Hamadeh IS, Ngwa BA, Gong Y: Drug induced osteonecrosis of the jaw. Cancer Treat Rev 2015; 41: 455–64 CrossRef MEDLINE |
| e3. | Papapoulos S, Chapurlat R, Libanati C, et al.: Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27: 694–701 CrossRef MEDLINE PubMed Central |
| e4. | Papapoulos S, Lippuner K, Roux C, et al.: The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 2015; 26: 2773–83 CrossRef MEDLINE PubMed Central |
| e5. | Guarneri V, Miles D, Robert N, et al.: Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181–8 CrossRef MEDLINE |
| e6. | Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F: Combination of zoledron acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 2013; 71: 1532–40 CrossRef MEDLINE |
| e7. | Giancola F, Campisi G, Lo Russo L, Muzio LL, Di Fede O: Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol (Roma) 2013; 4: 20–1. |
| e8. | Kim DW, Jung YS, Park HS, Jung HD: Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 2013; 51: e302–4 CrossRef MEDLINE |
| e9. | Dickinson M, Prince HM, Kirsa S, et al.: Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J 2009; 39: 304–16 CrossRef MEDLINE |
| e10. | Pautke C, Bauer F, Otto S, et al.: Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg 2011; 69: 84–91 CrossRef MEDLINE |
| e11. | Bonnick SL: Going on a drug holiday? J Clin Densitom 2011; 14: 377–83 CrossRef MEDLINE |
| e12. | Black DM, Schwartz AV, Ensrud KE, et al.: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927–38 CrossRef MEDLINE |
| e13. | Watts NB, Chines A, Olszynski WP, et al.: Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19: 365–72 CrossRef MEDLINE |
| e14. | Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG: Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008; 19: 1613–20 CrossRef MEDLINE PubMed Central |
| e15. | Gallagher AM, Rietbrock S, Olson M, van Staa TP: Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008; 23: 1569–75 CrossRef MEDLINE |
| e16. | Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119: S25–31 CrossRef |
| e17. | Qi WX, Tang LN, He AN, Yao Y, Shen Z: Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 2014; 19: 403–10 CrossRef MEDLINE |
| e18. | Whitaker M, Guo J, Kehoe T, Benson G: Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012; 366: 2048–51 CrossRef MEDLINE |
| e19. | Wardley A, Davidson N, Barrett-Lee P, et al.: Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869–76 CrossRef MEDLINE PubMed Central |
| e20. | Miksad RA, Lai KC, Dodson TB, et al.: Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011; 16: 121–32 CrossRef MEDLINE PubMed Central |
| e21. | Scoletta M, Arata V, Arduino PG, et al.: Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg 2013; 71: 994–9 CrossRef MEDLINE |
